Analysts Set Establishment Labs Holdings Inc. (NASDAQ:ESTA) PT at $57.60

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been given a consensus rating of “Moderate Buy” by the six research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $58.83.

ESTA has been the topic of a number of research analyst reports. JPMorgan Chase & Co. cut their price objective on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Citigroup raised their price objective on Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a research note on Tuesday, October 1st. Stephens restated an “overweight” rating and set a $68.00 price objective on shares of Establishment Labs in a report on Wednesday, August 7th. Finally, BTIG Research increased their target price on Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Monday.

Establishment Labs Stock Up 0.9 %

Shares of Establishment Labs stock opened at $42.91 on Monday. The stock’s 50-day moving average is $42.86 and its 200 day moving average is $46.66. Establishment Labs has a one year low of $16.96 and a one year high of $60.12. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -13.67 and a beta of 1.20. The company has a debt-to-equity ratio of 4.30, a current ratio of 4.44 and a quick ratio of 2.91.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The company had revenue of $44.12 million for the quarter, compared to analyst estimates of $43.10 million. During the same period last year, the business earned ($0.65) EPS. The business’s quarterly revenue was down 9.2% compared to the same quarter last year. Equities research analysts anticipate that Establishment Labs will post -2.27 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ESTA. Hood River Capital Management LLC bought a new position in Establishment Labs during the 2nd quarter valued at $43,000. California State Teachers Retirement System lifted its position in shares of Establishment Labs by 14.5% during the first quarter. California State Teachers Retirement System now owns 17,096 shares of the company’s stock valued at $870,000 after purchasing an additional 2,167 shares in the last quarter. Swiss National Bank boosted its holdings in Establishment Labs by 13.6% during the first quarter. Swiss National Bank now owns 37,500 shares of the company’s stock worth $1,909,000 after purchasing an additional 4,500 shares during the last quarter. Nkcfo LLC bought a new stake in Establishment Labs in the 2nd quarter worth about $227,000. Finally, Concurrent Investment Advisors LLC purchased a new stake in Establishment Labs in the 1st quarter valued at about $263,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.